Company Analysis
Sign in

Tiziana Life Sciences Ltd. (TLSA)

Nasdaq: TLSA · Pharmaceutical Preparations · London, England, GB · filing with the SEC since 2017
Full chart Alerts Compare
Grade4.6
◀ Past 6.1● Present 2.8▶ Future 5.2
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2024, as filed
Revenuen/a
Net income-$11.9M+32.9%
Earnings per share$-0.11+35.3%
Operating cash flow-$1.5M+90.3%
Cash$3.7M+214.8%
Debtn/a
Shareholders’ equity$3.9M-28.9%
Shares, diluted106.7M+4.1%
Return on equity-301.4%
The recordfrom its filings
Filings in 202649
Newest filingNov 12 · 6-K
Annual reportMay 1, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$1.0M
Patents granted4
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
161718192021222324
As filed, in USD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton TLSA · research, not advice